Erlotinib versus standard chemotherapy as first-line treatment for Euro- pean patients with advanced EGFR mutation- positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246. [6] Pao W, Miller VA, Politi KA, Riely GJ...